CN109069567A - 一种预防或治疗糖尿病性神经损伤及其相关病症的方法 - Google Patents

一种预防或治疗糖尿病性神经损伤及其相关病症的方法 Download PDF

Info

Publication number
CN109069567A
CN109069567A CN201680073671.8A CN201680073671A CN109069567A CN 109069567 A CN109069567 A CN 109069567A CN 201680073671 A CN201680073671 A CN 201680073671A CN 109069567 A CN109069567 A CN 109069567A
Authority
CN
China
Prior art keywords
plasminogen
diabetic
day
mouse
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680073671.8A
Other languages
English (en)
Inventor
李季男
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Talengen Institute of Life Sciences Co Ltd
Original Assignee
Talengen Institute of Life Sciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Talengen Institute of Life Sciences Co Ltd filed Critical Talengen Institute of Life Sciences Co Ltd
Publication of CN109069567A publication Critical patent/CN109069567A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Abstract

纤溶酶原在预防和/或治疗糖尿病性神经疼痛、神经超敏、修复神经组织损伤方面的作用。因此，纤溶酶原可能成为全新的预防和治疗糖尿病神经疼痛的策略。

Description

PCT国内申请，说明书已公开。

Claims (14)

  1. PCT国内申请，权利要求书已公开。
CN201680073671.8A 2015-12-18 2016-12-16 一种预防或治疗糖尿病性神经损伤及其相关病症的方法 Pending CN109069567A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2015097943 2015-12-18
CNPCT/CN2015/097943 2015-12-18
PCT/CN2016/110449 WO2017101867A1 (zh) 2015-12-18 2016-12-16 一种预防或治疗糖尿病性神经损伤及其相关病症的方法

Publications (1)

Publication Number Publication Date
CN109069567A true CN109069567A (zh) 2018-12-21

Family

ID=59055773

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680073671.8A Pending CN109069567A (zh) 2015-12-18 2016-12-16 一种预防或治疗糖尿病性神经损伤及其相关病症的方法

Country Status (8)

Country Link
US (1) US11400142B2 (zh)
EP (1) EP3395353B1 (zh)
JP (2) JP6749412B2 (zh)
CN (1) CN109069567A (zh)
CA (1) CA3008694C (zh)
DK (1) DK3395353T3 (zh)
TW (1) TWI653981B (zh)
WO (1) WO2017101867A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113597313A (zh) * 2019-01-24 2021-11-02 先觉药业咨询公司 用于治疗和预防微血栓形成的纤溶酶原
WO2022105789A1 (zh) * 2020-11-17 2022-05-27 泰伦基国际有限公司 一种提高ngf水平的方法和药物

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115845037A (zh) * 2015-12-18 2023-03-28 泰伦基国际有限公司 一种用于预防或治疗急性及慢性血栓的方法
TWI623321B (zh) 2015-12-18 2018-05-11 Talengen Institute Of Life Sciences Co Ltd Method for preventing and treating cervical erosion
CN108463236A (zh) 2015-12-18 2018-08-28 泰伦基国际有限公司 一种预防或治疗放射性和化学性损伤的方法
JP6682008B2 (ja) 2015-12-18 2020-04-15 タレンゲン インターナショナル リミテッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 糖尿病性腎症を予防及び治療するための方法
EP3395360A4 (en) 2015-12-18 2019-06-12 Talengen International Limited METHOD FOR PREVENTING OR TREATING DIABETIC RETINOPATHY
CN110114082A (zh) 2016-12-15 2019-08-09 泰伦基国际有限公司 一种预防和治疗脂肪代谢紊乱及其相关病症的方法
CN110121358A (zh) 2016-12-15 2019-08-13 泰伦基国际有限公司 一种预防和治疗肺纤维化的方法
TW201829448A (zh) 2016-12-15 2018-08-16 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備預防或治療肥胖症及疾病倂發的肥胖的藥物中的用途
TWI677348B (zh) 2016-12-15 2019-11-21 大陸商深圳瑞健生命科學研究院有限公司 一種改善心臟病變的方法
CN110139667A (zh) 2016-12-15 2019-08-16 泰伦基国际有限公司 一种使胰高血糖素、胰岛素恢复正常平衡的方法
WO2018233604A1 (zh) 2017-06-19 2018-12-27 泰伦基国际有限公司 一种调控glp-1/glp-1r的方法和药物
JP2023515916A (ja) * 2020-01-17 2023-04-17 タレンゲン インターナショナル リミテッド 神経損傷及び関連障害を治療するための方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1191856C (zh) * 1998-09-29 2005-03-09 勒芬研究与发展公司 可在体内减少α2－抗纤溶酶的化合物在制备用于治疗局部缺血性中风的组合物中的用途
TW200803890A (en) * 2006-02-22 2008-01-16 Bausch & Lomb Compositions and methods for effecting controlled posterior vitreous detachment

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2295925A1 (en) 1997-06-26 1999-01-07 Karolinska Innovations Ab Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo
US6899877B2 (en) 1999-03-09 2005-05-31 Minu, L.L.C. Process for generating plasmin in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina
WO2001024815A1 (en) 1999-10-07 2001-04-12 Human Genome Sciences, Inc. Plasminogen-like polynucleotides, polypeptides, and antibodies
US7067492B2 (en) 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
US20030198666A1 (en) * 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US7202066B2 (en) 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
WO2003066842A2 (de) 2002-02-06 2003-08-14 Trommsdorff Gmbh & Co. Kg Arzneimittel Verfahren zur herstellung von rekombinanten proteinen in mikroorganismen
EP2322200A3 (en) 2002-10-29 2011-07-27 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
CN1451746A (zh) 2003-03-20 2003-10-29 广州市启源生物科技有限公司 人纤溶酶原Kringle 5缺失突变重组多肽
US20050250694A1 (en) * 2003-10-10 2005-11-10 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
CN1946352A (zh) 2004-04-09 2007-04-11 狄科特康坦特公司 递送药物至眼以治疗后段疾病的方法和物品
CN100529085C (zh) 2005-12-30 2009-08-19 上海新生源医药研究有限公司 重组人纤溶酶原Kringle 5(hk5)生产方法
CN101002888A (zh) 2006-01-16 2007-07-25 陈维森 复方糖尿康
CN101563100B (zh) 2006-08-28 2013-08-07 李季男 用于预防和治疗牙周病、改善牙周创伤愈合以及促进口腔健康的新药物靶标
KR20100097113A (ko) 2007-10-23 2010-09-02 가부시키가이샤 이야쿠 분지 셋케이 겐쿠쇼 Ｐａｉ－１ 생산 억제제
PL2220221T3 (pl) 2007-11-29 2015-07-31 Grifols Therapeutics Inc Rekombinacyjnie zmodyfikowana plazmina
US20090208448A1 (en) 2008-02-15 2009-08-20 Solomon Keith R Inhibition of angiogenesis
JP2009196927A (ja) 2008-02-21 2009-09-03 Chemo Sero Therapeut Res Inst 血管障害に起因する網膜障害の進展阻害または治療剤
CN102250210B (zh) 2010-05-21 2014-05-28 厦门大学 人纤溶酶原Kringle 5短肽、其药物组合物、用途和编码该种短肽的多核苷酸
CN102121023B (zh) 2010-12-22 2012-07-04 中山大学 突变型人纤溶酶原kringle5及其制备方法及应用
EP2661493B1 (en) 2011-01-05 2016-03-30 ThromboGenics N.V. Plasminogen and plasmin variants
CN102154253A (zh) 2011-01-06 2011-08-17 郑州大学 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途
WO2013024074A1 (en) 2011-08-12 2013-02-21 Thrombogenics N.V. Plasminogen and plasmin variants
US9718760B2 (en) 2012-10-31 2017-08-01 The Regents Of The University Of Michigan Plasminogen activator inhibitor-1 inhibitors and methods of use thereof
US9079739B2 (en) 2012-11-02 2015-07-14 The Procter & Gamble Company Apparatus for controlling the nip force/pressure between two rotating cylinders
TN2016000048A1 (en) 2013-08-13 2017-07-05 Sanofi Sa Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
TW201722994A (zh) 2013-08-13 2017-07-01 賽諾菲公司 胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途
CN104789544B (zh) 2014-01-16 2019-11-26 中国科学院福建物质结构研究所 重组pai-1抑制剂、包含其的组合物及其用于治疗和检测用途
CN107249622B (zh) 2014-12-19 2021-08-03 普罗米蒂克生物治疗有限公司 包含纤溶酶原的药物组合物和其用途
TWI801331B (zh) 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
JP6682008B2 (ja) 2015-12-18 2020-04-15 タレンゲン インターナショナル リミテッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 糖尿病性腎症を予防及び治療するための方法
CN115845037A (zh) 2015-12-18 2023-03-28 泰伦基国际有限公司 一种用于预防或治疗急性及慢性血栓的方法
EP3395360A4 (en) 2015-12-18 2019-06-12 Talengen International Limited METHOD FOR PREVENTING OR TREATING DIABETIC RETINOPATHY
CN110139667A (zh) 2016-12-15 2019-08-16 泰伦基国际有限公司 一种使胰高血糖素、胰岛素恢复正常平衡的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1191856C (zh) * 1998-09-29 2005-03-09 勒芬研究与发展公司 可在体内减少α2－抗纤溶酶的化合物在制备用于治疗局部缺血性中风的组合物中的用途
TW200803890A (en) * 2006-02-22 2008-01-16 Bausch & Lomb Compositions and methods for effecting controlled posterior vitreous detachment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JING SIMA等: "The effect of angiostatin on vascular leakage and VEGF expression in rat retina", 《FEBS LETTERS》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113597313A (zh) * 2019-01-24 2021-11-02 先觉药业咨询公司 用于治疗和预防微血栓形成的纤溶酶原
WO2022105789A1 (zh) * 2020-11-17 2022-05-27 泰伦基国际有限公司 一种提高ngf水平的方法和药物

Also Published As

Publication number Publication date
CA3008694C (en) 2022-11-29
JP6749412B2 (ja) 2020-09-02
JP2020090543A (ja) 2020-06-11
US11400142B2 (en) 2022-08-02
EP3395353A4 (en) 2019-06-12
TWI653981B (zh) 2019-03-21
DK3395353T3 (da) 2024-03-11
EP3395353A1 (en) 2018-10-31
EP3395353B1 (en) 2024-03-06
TW201722465A (zh) 2017-07-01
CA3008694A1 (en) 2017-06-22
WO2017101867A1 (zh) 2017-06-22
JP2019500423A (ja) 2019-01-10
US20180369345A1 (en) 2018-12-27

Similar Documents

Publication Publication Date Title
CN109069567A (zh) 一种预防或治疗糖尿病性神经损伤及其相关病症的方法
TWI725092B (zh) 纖溶酶原在製備預防或治療糖尿病腎病或其相關病症之藥劑上的用途
JP7117012B2 (ja) 糖尿病網膜症を予防または治療するための方法
TWI624268B (zh) 纖溶酶原在製備藥劑上的用途及包括纖溶酶原之藥劑
JP6815413B2 (ja) 肝組織損傷及びその関連疾患を予防及び治療するための方法
CN110114080A (zh) 一种预防和治疗皮肤纤维化的方法
CN108463236A (zh) 一种预防或治疗放射性和化学性损伤的方法
TW202123962A (zh) 一種預防和治療腎纖維化的方法
CN106890324A (zh) 一种预防和治疗糖尿病肾病的方法
CN106890325A (zh) 一种预防或治疗糖尿病性神经损伤及其相关病症的方法
CN106890318A (zh) 一种预防和治疗糖尿病性心脏病的新方法
CN106890319A (zh) 一种预防或治疗糖尿病性视网膜病变的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination